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EXPERT’S CORNER: A  PERSONAL APPROACH
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Fecal  microbiota  transplantation  (FMT)  represents  the most
promising  free-antibiotic  therapy  in the management  of
patients  with  infection  by  Clostridium  difficile, recurrent
or  refractory  to  treatment  with  antibiotics.  FMT’s  superior-
ity  over  conventional  treatment  has been proven in multiple
series  of  cases  and recently  in experimental  prospective  ran-
domized  clinical  trials  with  a resolution  of  the  infection  in
over  90%  of  patients.1
FMT  occurs  when  intestinal  microorganisms  are  infused
with  a  suspension  from  a healthy  donor  into  a  sick  patient  for
the  purposes  of  restoring  altered  microbiota.  The  first  known
description  of the use  of  human  feces  as  a therapeutic  agent
comes  from  China.  During  the  IV  century,  Ge  Hong  prescribed
--  in  the  emergency  medicine  pocket  book  --  the  intake  of
feces  for  different  diseases.  The  success  of  fecal  microbiota
transplantation  in modern  medicine  was  first  described  by
Eiseman  et  al. in  1958, administrating  microbiota  in enemas
to  patients  with  pseudomembranous  colitis.2,3
C.  difficile  is  a  Gram-positive  spore-forming  bacteria  iso-
lated  in  1935  and  described  for  the first  time  as  a cause  of
diarrhea  and  pseudomembranous  colitis  in a patient  in 1978.
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In the last  three  decades  we  have  witnessed  the  increase
in the incidence  and  severity  of  infectious  profiles  by  C.
difficile,  making  it a serious  health  issue, increasing  mor-
bidity  and mortality  in hospitalized  patients  as  well  as  in
outpatients.  The  incidence  of infection  by  C.  difficile  in the
community  has  increased  5.3  times  from  1991  to  2005  and  in
these  outpatients  the  disease  occurs  in young  adults  without
comorbidities  who  lack  traditional  risk  factors  like  the  expo-
sure  to  antibiotics  and  recent  hospitalization.  This  suggests
new  risk  factors  and new  forms  of  transmission.3,4
One  of  the  factors  which  has  contributed  to the increase
in the number  of cases  of  infection  by  C.  difficile  is  the  pres-
ence  of  a  new,  more  virulent,  quinolone-resistant  strain,
which  produces  16  times  more  toxin  A  and 23  times  more
toxin  B,  in addition  to  a  third  toxin,  which  has  enterotoxi-
genic  activity  in vitro.5 Moreover,  this  new  strain  produces
more  spores,  conditioning  a  greater  pollution  in the  envi-
ronment,  thereby  increasing  the risk  of  spreading.  This
epidemic  strain  is  associated  with  a  higher  incidence  of  com-
plicated  cases  and  a higher  mortality  rate.  Initially  identified
by  a  restriction  endonuclease  analysis  and  denominated  as  BI
(1980),  it  is  currently  referred  to as  Type 1  (NAP1)  by  pulsed
fields  analysis  or  ribotype  027  by  ribotypification.  This  NAP1
strain  has spread  widely  in  the US;  nevertheless,  very  few
clinics  are aware  of its presence  due  to  its  characteristics.1,4
Current  recommendations  to  decide  on  a treatment  for
patients  with  infection  by  C.  difficile  are  based on  clinical
severity.  Patients  with  mild  infections  may  be  treated  with
metronidazole  500  mg,  administered  orally  3 times a day,  or
vancomycin  125 mg,  administered  orally  4 times  a  day for
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10  days.  Severe  cases  are treated  with  vancomycin  125 mg,
administered  orally  4  times  a  day  for  10  days. Complicated
severe  cases  are  treated  with  a  combination  of  vancomycin
500  mg,  administered  orally  4 times  a day,  plus  metronida-
zole  500  mg  IV  every 8  h  and rectal  vancomycin  (vancomycin
500  mg  in  500  ml  of  saline  solution  in enema)  4 times  a  day
in  case  of  the  presence  of  ileus.5
However,  one of  the challenging  aspects  in  the man-
agement  of  patients  with  a  C. difficile  infection  is  the
recurrence  of the  disease  after  a successful  treatment.  It
is  considered  a  recurrence  when symptoms  restart  within
the  first  8 weeks  after  the  end  of  treatment.  Recurrence
rates  after  treatment  with  metronidazole  and  vancomycin
are  similar  (20.2%  and  18.4%,  respectively)6.  For the treat-
ment  of  recurrences,  we  recommend  the  same  treatment
that  was  used  during  the  initial  episode,  coupled  with  a
suspension  of  any  antibiotics  the patient  may  be  taking  to
allow  the  restoration  of  the intestinal  microflora.  If the
new  episode  is  severe,  vancomycin  should be  utilized. Some
experts  recommend  giving  pulses  of  vancomycin  in the  case
of  a  second  recurrence.  Other  antibiotics,  like  rifaximin  and
fidaxomicin,  have  been  tested  in cases  of recurrence  and
obtained  variable  results  and,  overall,  a greater  cost7,8.  Nei-
ther  of  these  is  currently  recommended  for  recurring  cases.
In  the  context  of  treating  a  recurrent  C.  difficile
infection,  we  are  confronted  with  a  grand  paradigm;  the
recurring  infection  is  secondary  to  a disruption  of  the  colonic
microflora  started  by  the antibiotic  therapy  and  perpetuated
by  metronidazole  or  vancomycin.  The  antibiotics  destroy
the  bacteria,  but  also  destroy  the  intestinal  microbiota,
which  is  vital  to  maintaining  health,  immunity  and colonic
metabolism.  The  risk  of  recurrence  is  greater  in patients
with  a  previous  recurrence,  increasing  by  20%  after  the  first
episode,  up  to  40%  with  the first  recurrence  and  up  to  more
than  60%  after  2 recurrences4,9.
There  is  a decrease  in the diversity  of  fecal  microbiota  in
patients  with  recurrent  diarrhea  due  to a C.  difficile  infec-
tion.  This  decrease  can be  observed,  for  the  most  part,  in
the  concentration  of  the  specie  Bacteroides  and  Fermicutes.
Because  of  this,  a  treatment  without  antibiotics,  preser-
ving  and  restoring  microbiotic  diversity,  can  represent  a  new
strategy  to  achieve  the  prevention  and  treatment  of  recur-
ring  C.  difficile  infections10.  FMT has been  demonstrated  to
be  an  effective  alternative  in the  treatment  of refractory
C.  difficile  infections,  and  is  the most  radical  and direct
method  to  change  the composition  of  the colon microbiota2.
To  perform  a  FMT,  a feces  sample  from  a  healthy  person
is  required.  In our  hospital  we  performed  a  simple  ques-
tionnaire  looking  for  a  person  without  comorbidities,  with
an  adequate  BMI,  who  did  not  have  any antecedent  of  pre-
vious  hospitalization  or  use  of  antibiotics  within  the last  3
months.  We  performed  general  examinations  (blood  count,
blood  chemistry)  a  viral  profile  (HBVAgs,  Antibodies  against
HCV  and  HIV),  a  coprological  is  conducted  as  well  as  a  single
stool  specimen  ova  and  parasite  examination  and  toxins  A
and  B for  C. difficile  in  feces.
Upon  deciding  that the  patient  with  a C.  difficile  infec-
tion  is  a  candidate  for  FMT,  the use  of  antibiotics  was
suspended  for  48--72  h  and  a  nasojejunal  probe  was  placed
and  its  adequate  placement  verified by  simple  X-rays.  One
day  before  the transplant,  4 packets  of  Nulitely  (109.6  g
each)  were  administered,  each  one  diluted  in  4 L of water.
On  the day  of the  transplant  a  fecal material  sample  is
requested  from  the  donor  in  the morning,  and  laboratory
personnel  homogenize  the sample  in  a  saline  solution  and
filter  it, obtaining  approximately  50  ml of  microbiotic  solu-
tion.  The  FMT  is administered  by  means  of the nasojejunal
probe.  In case  it does  not  advance  to  the small intestine,
an  endoscope  is  used to  instill  the FMT  directly  into  the
duodenum.  The  case  can  be used  as  an  alternate  method
of administering  a colonoscopy,  as  the situation  warrants.
The  therapy  is  considered  to  be effective  when  the  diarrhea
disappears  after  the administration  of  the FMT.
The  superiority  of the FMT over  treatment  with  antibi-
otics  has  been  demonstrated  in multiple  publications.  The
series  of  cases  show  favorable  responses  in  more  than  90%
of  cases11.  Recently,  a  controlled  randomized  study  was  per-
formed,  comparing  the  effectiveness  of FMT (n = 16)  against
treatment  with  antibiotics,  observing  the resolution  of  the
disease  in 94% of  cases (3 patients  received  a double  FMT
infusion)12. Now,  there  are  studies  that  show its  utility  in
seriously  ill  patients  or  immunosuppressed  patients  with
recurring  or  refracting  C.  difficile  infections,  observing  a
recovery  in  89% (n  =  80).  In  our  center,  we  have  used  the
FMT  in refractory  as  well  as  recurring  cases.  For  the most
part,  the patients  are hospitalized  and  suffering  from  multi-
ple  comorbidities.  We  have  obtained  a  resolution  of diarrhea
of  87%,  and  were  able  to avoid  surgical  management  and
reduce  morbi-mortality  in  these patients.  Recently,  meth-
ods  have  been  developed  to  freeze  the microbiota  for the
FMT in capsules  at  −80C◦ and  study  its  effects  in cases  of
refractory  C.  difficile  infections,  with  an  observed  effective-
ness of 90%13.  None  of  the  studies  have  reported  significant
side  effects.  Other  uses that  the FMT has  been  used for  have
been in patients  with  a C.  difficile  infection  and  inflamma-
tory bowel  disease  (IBD), including  a therapeutic  proposal  in
cases  of  refractory  IBD1.
By what  has  been  documented,  we  can conclude  that  the
FMT has shown  its usefulness  in patients  with  a  recurrent  or
refractory  C.  difficile  infection,  and as  a medical  treatment
even  for  patients  that  are  seriously  ill  or  with  some  degree
of  immunosuppression.  With  the increase  in the  incidence
and  severity  of C.  difficile  infections,  the FMT  has  a very
important  role  to  play  in the  combating  of this  disease.  Our
experience  underlines  the  fact that  treatment  with  FMT  in
Mexico  is  a  reality.  The  requirements  for  its  implementation
and  the technical  process  are simple,  bringing  the option  of
a  cure  to  the  majority  of patients  managed  with  this therapy,
which  is  free  of  antibiotics  and  serious  adverse  effects.
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